Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California. Show more

1851 HARBOR BAY PARKWAY, ALAMEDA, CA, UNITED STATES, 94502, Alameda, CA, 94502, USA

https://www.exelixis.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

12.96B

52 Wk Range

$33.76 - $57.57

Previous Close

$51.24

Open

$51.25

Volume

2,372,576

Day Range

$50.80 - $52.70

Enterprise Value

12.03B

Cash

281.4M

Avg Qtr Burn

N/A

Insider Ownership

1.85%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COTELLIC (cobimetinib) Details Metastatic melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COMETRIQ (cabozantinib) Details Metastatic MTC (Medullary Thyroid Cancer)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CABOMETYX (cabozantinib) Details Renal cell carcinoma, neuroendocrine tumors (NETs)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + atezolizumab Details Metastatic colorectal cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CABOMETYX (cabozantinib) + atezolizumab Details Solid tumor/s, Cancer, Castration-resistant prostate cancer	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib Details Neuroendocrine tumor	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib Details Solid tumor/s, Kidney cancer, Renal cell carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + KEYTRUDA (Pembrolizumab) Details Cancer, Head and neck squamous cell carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belzutifan + Zanzalintinib (Combination Therapy) Details Recurrent Clear Cell Renal Cell Carcinoma During Or After Adjuvant Anti-PD-(L)1 Therapy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + Immune Checkpoint Inhibitor Details Resected Stage II/III Colorectal Cancer (MRD-Positive)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + Nivolumab (Combination Therapy) Details Neoadjuvant Locally Advanced Or Surgically Challenging Clear Cell Renal Cell Carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib (Kinase Inhibitor) Details Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (Previously Treated With Immune Checkpoint Inhibitors)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib +/- atezolizumab Details Solid tumor/s, Cancer, Carcinoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + AB521 Details Cancer, Kidney cancer, Renal cell carcinoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib + Nivolumab ± Relatlimab Details Solid tumor/s, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CBX-12 Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CABOMETYX (cabozantinib) + Nivolumab + Ipilimumab Details Cancer, Solid tumor/s, Kidney cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XL495 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.